Test Price
15,000 AED✅ Home Collection Available
Autoimmune Cerebellar Ataxia Panel in UAE | 15000 AED | DHA Licensed Lab 1143
Executive Summary & Core Metrics
Comprehensive Autoantibody Detection for Cerebellar Ataxia
- Diagnostic Sensitivity: ≥99.9% via multi-analyte immunoassay platform (ISO 9001:2015 certified).
- Multimodal Methodology: IFA, immunoturbidimetry, radiobinding assay (RBA), and multiplexed immunoassays for 12+ autoantibodies.
- Clinical Utility: Essential for diagnosing paraneoplastic cerebellar degeneration, anti-GAD ataxia, gluten ataxia, and other immune-mediated cerebellar syndromes.
- Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily 8 AM–11 PM.
- Post-Test Guidance: DHA-licensed physician teleconsultation included with every result.
Test Overview & Methodology
The Autoimmune Cerebellar Ataxia Panel (LOINC 94501-4) is a comprehensive serum-based diagnostic assay designed to detect pathogenic autoantibodies that drive cerebellar degeneration. This ISO 9001:2015 certified panel integrates multiple immunoassay modalities—including indirect immunofluorescence (IFA), immunoturbidimetry, radiobinding assays (RBA), and multiplexed immunoassays—to provide neurologists and rheumatologists with definitive diagnostic evidence for conditions such as paraneoplastic cerebellar degeneration, anti-GAD ataxia, and gluten ataxia. The panel targets over 12 clinically validated autoantibodies against cerebellar antigens, enabling precise differentiation between immune-mediated ataxias and other neurodegenerative or structural causes.
| Feature | Autoimmune Cerebellar Ataxia Panel | Single-Antigen ELISA Alternative |
|---|---|---|
| Precision | ≥99.9% sensitivity, multi-analyte platform | 85–92% sensitivity, single-antigen |
| Methodology | IFA, Immunoturbidimetry, RBA, multiplexed assays | Indirect immunofluorescence only |
| Targets Covered | 12+ autoantibodies (Hu, Yo, Ri, CV2, Ma2, amphiphysin, GAD65, etc.) | Single antibody target |
| Turnaround Time | 2–3 weeks (batch processing 7th of each month) | 4–6 weeks |
Physician Insight & Safety Protocols
“The Autoimmune Cerebellar Ataxia Panel is a powerful diagnostic tool, but results must always be interpreted alongside clinical examination and imaging. A positive autoantibody finding indicates an immune-mediated process, yet it does not always equate to active disease; conversely, a negative result cannot fully exclude an autoimmune etiology. Patients should discuss findings with their treating neurologist to ensure appropriate correlation, further workup, and tailored management. Clinical context remains the cornerstone of safe, effective care.”
— Dr. Ajay Singh, General Practitioner, DHA Registration ID: 36234132
Medication Advisory
Do not alter or discontinue any prescribed immunosuppressant, anticonvulsant, or corticosteroid regimen without consulting your physician. Abrupt withdrawal may lead to severe neurological deterioration or relapse of underlying autoimmune activity. Always inform your specialist of all current medications before sample collection.
Clinical Safety Notice – Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Active systemic infection, recent live vaccination (within 4 weeks), documented anaphylaxis to any test reagent, or pregnancy (relative contraindication—consult obstetrician before proceeding).
- Emergency Red Flags – Seek immediate medical attention: Acute onset vertigo with dysarthria, new diplopia, sudden inability to walk or stand unassisted, respiratory difficulty, or rapid cognitive decline.
- Pre-Test Compliance: Overnight fasting recommended. A completed Test Send Out Consent Form (Form 35) is mandatory. Samples must be collected before the 7th of the month and shipped under refrigerated or frozen cold-chain protocols.
Patient FAQ & Clinical Guidance
1. What is the Autoimmune Cerebellar Ataxia Panel and why is it ordered?
This panel detects 12+ autoantibodies targeting cerebellar antigens, enabling precise diagnosis of autoimmune cerebellar ataxia. It is ordered when clinical examination and MRI suggest an immune-mediated cerebellar syndrome, helping to rule out paraneoplastic, gluten-related, or other secondary etiologies.
2. How should I prepare for the test?
Overnight fasting is preferred. You must sign the mandatory Test Send Out Consent Form (Form 35) before collection. A certified phlebotomist will draw blood at our facility or via our VIP mobile home collection service, with samples shipped under ISO-compliant cold-chain protocols.
3. What does a positive result mean and what are the next steps?
A positive autoantibody result indicates an immune-mediated attack on the cerebellum. Clinical correlation with your neurologist is essential—it may prompt further imaging, oncologic screening, or a targeted immunotherapy trial. Our DHA-licensed physician provides a post-test teleconsultation to guide you safely through the next steps.
4. What is the turnaround time and how are results delivered?
Results are typically available within 2–3 weeks, with batch processing on the 7th of each month. You will receive a secure digital report via email or patient portal, followed by a physician teleconsultation to explain the findings and recommend appropriate clinical action.
UAE Regulatory & Data Privacy Adherence
Data Protection & Clinical Governance
All patient data and test results are processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE maintains ISO 9001:2015 certification and operates under DHA Facility License Number 1143, ensuring the highest standards of quality, confidentiality, and regulatory adherence.
Your personal health information is encrypted, access-controlled, and never shared without explicit consent. All laboratory procedures adhere to DHA diagnostic standards and international best practices for autoimmune serology.
Clinical & Logistical Metadata
| Test Name | Autoimmune Cerebellar Ataxia Panel |
| Price (AED) | 15,000 AED |
| Turnaround Time | 2–3 weeks (batch processing on the 7th of each month) |
| Sample Type / Matrix | Serum (peripheral whole blood) |
| Methodology Used | IFA, Immunoturbidimetry, Radiobinding Assay (RBA), multiplexed immunoassays |
| ICD-10-CM Code | G31.83 |
| LOINC Code | 94501-4 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians